rs81002806

Variant names:

• chr13-32370560-A-G
• rs81002806
• NM_000059.4:c.8487+3A>G

Your query was ambiguous. Multiple possible variants found:

• chr13-32370560-A-G
• chr13-32370560-A-T

Variant summary

Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2 PP5_Very_Strong

The NM_000059.4(BRCA2):​c.8487+3A>G variant causes a splice region, intron change. The variant allele was found at a frequency of 0.00000137 in 1,457,264 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).

• Frequency:
  • Genomes: not found (cov: 32)
  • Exomes 𝑓: 0.0000014 (0 hom.)
• Consequence: BRCA2 NM_000059.4 splice_region, intron
• Scores: Splicing: ADA: 0.9945
• Clinical Significance: Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:10 U:1 O:1
• Conservation: PhyloP100: 3.73

Genes affected

BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]

ACMG classification

Verdict is Pathogenic. Variant got 10 ACMG points.

• PM2: Very rare variant in population databases, with high coverage
• PP5: Variant 13-32370560-A-G is Pathogenic according to our data. Variant chr13-32370560-A-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 52603.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr13-32370560-A-G is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
BRCA2	NM_000059.4	c.8487+3A>G		splice_region_variant, intron_variant	Intron 19 of 26	ENST00000380152.8	NP_000050.3

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
BRCA2	ENST00000380152.8	c.8487+3A>G		splice_region_variant, intron_variant	Intron 19 of 26	5	NM_000059.4	ENSP00000369497.3
BRCA2	ENST00000530893.7	c.8118+3A>G		splice_region_variant, intron_variant	Intron 19 of 26	1		ENSP00000499438.2
BRCA2	ENST00000614259.2	n.*545+3A>G		splice_region_variant, intron_variant	Intron 18 of 25	2		ENSP00000506251.1

Frequencies

GnomAD3 genomes Cov.: 32

GnomAD4 exome AF: 0.00000137 AC: 2 AN: 1457264 Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0 AN XY: 725356

Gnomad4 AFR exome AF: 0.00

Gnomad4 AMR exome AF: 0.00

Gnomad4 ASJ exome AF: 0.00

Gnomad4 EAS exome AF: 0.00

Gnomad4 SAS exome AF: 0.00

Gnomad4 FIN exome AF: 0.00

Gnomad4 NFE exome AF: 0.00000181

Gnomad4 OTH exome AF: 0.00

GnomAD4 genome Cov.: 32

ClinVar

Significance: Pathogenic/Likely pathogenic

Submissions summary: Pathogenic:10 Uncertain:1 Other:1

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

Familial cancer of breast Pathogenic:2

Jul 15, 2020

Genetics and Molecular Pathology, SA Pathology

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Nov 02, 2023

Baylor Genetics

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Hereditary cancer-predisposing syndrome Pathogenic:2

Sep 07, 2023

Ambry Genetics

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

The c.8487+3A>G intronic variant results from an A to G substitution 3 nucleotides after coding exon 18 in the BRCA2 gene. This nucleotide position is well conserved in available vertebrate species. This alteration was seen in conjunction with a second BRCA2 mutation in a child diagnosed with Fanconi anemia at age 11 months (Myers K et al. Pediatr Blood Cancer. 2012 Mar;58(3):462-5). RNA analyses have found that this alteration causes aberrant splicing leading to skipping of coding exon 18 (Ambry internal data; Acedo A et al. Breast Cancer Res. 2012 May 25;14(3):R87). In silico splice site analysis predicts that this alteration will weaken the native splice donor site. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. However, because this variant is identified in one or more patients with Fanconi Anemia it may be hypomorphic and thus, carriers of this variant and their families may present with reduced risks, and not with the typical clinical characteristics of a high-risk pathogenic BRCA2 alteration. As risk estimates are unknown at this time, clinical correlation is advised. -

Jan 03, 2024

Color Diagnostics, LLC DBA Color Health

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant causes an A to G nucleotide substitution at the +3 position of intron 19 splice donor site of the BRCA2 gene. Splice site prediction tools predict that this variant may have a significant impact on RNA splicing. Multiple RNA studies have shown that this variant causes an in-frame skipping of exon 19 that encodes DNA binding domain (PMID: 22632462; ClinVar SCV000668580.3, SCV001446381.1). This variant has been reported in individuals affected with hereditary breast and/or ovarian cancer (PMID: 27376475, Color internal data). This variant has also been observed in compound heterozygous state with c.3264dupT in a child affected with Fanconi anemia with family history of ovarian and pancreatic cancers (PMID: 21548014) and in homozygosity in an unrelated child affected with Fanconi anemia (ClinVar SCV001446381.1, communication with an external laboratory). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA2 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -

Breast-ovarian cancer, familial, susceptibility to, 2 Pathogenic:1 Uncertain:1

Dec 23, 2003

Breast Cancer Information Core (BIC) (BRCA2)

Significance: Uncertain significance

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

Aug 20, 2020

University of Washington Department of Laboratory Medicine, University of Washington

Significance: Likely pathogenic

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

Cerebral palsy;C1384666:Hearing impairment;C4022738:Neurodevelopmental delay Pathogenic:1

Jan 10, 2019

Genomic Medicine Lab, University of California San Francisco

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

BRCA2-related disorder Pathogenic:1

Mar 24, 2024

PreventionGenetics, part of Exact Sciences

Significance: Pathogenic

Review Status: no assertion criteria provided

Collection Method: clinical testing

The BRCA2 c.8487+3A>G variant is predicted to interfere with splicing. This variant has been reported along with a second causative variant in individuals with medulloblastoma and Fanconi anemia (DeWire et al. 2009. PubMed ID: 19530235; Chandrasekharappa et al. 2013. PubMed ID: 23613520; Internal Data, PreventionGenetics). This variant has been reported in the heterozygous state in one individual in a cohort study of prospective hereditary breast and ovarian cancer patients (Schenkel et al. 2016. PubMed ID: 27376475). This variant has not been reported in a large population database, indicating this variant is rare. RT-PCR studies suggest this variant impacts mRNA splicing and results in in-frame skipping of exon 19 (Acedo et al. 2012. PubMed ID: 22632462). This variant is interpreted as pathogenic/likely pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/52603/). This variant is interpreted as pathogenic. -

not provided Pathogenic:1

Dec 04, 2020

Quest Diagnostics Nichols Institute San Juan Capistrano

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant has been reported in an individual with Fanconi Anemia type D1 in the published literature (PMIDs: 19530235 (2009), 21548014 (2012) and 23613520 (2013)). Analysis of this variant using software algorithms for the prediction of the effect of nucleotide changes on BRCA2 mRNA splicing yielded inconclusive predictions. A splicing functional assay, however, showed that this variant results in exon 19 skipping and a significant reduction of the canonical transcript (PMID: 22632462 (2012)). This variant has not been reported in large, multi-ethnic general populations. Therefore, we predict that this variant is likely pathogenic. -

Malignant tumor of breast Pathogenic:1

-

Department of Pathology and Laboratory Medicine, Sinai Health System

Significance: Likely pathogenic

Review Status: no assertion criteria provided

Collection Method: clinical testing

The BRCA2 c.8487+3A>G variant was identified in dbSNP (ID: rs81002806) “With uncertain significance allele”, HGMD as a “Disease causing mutation”, ClinVar database, the BIC database (1 X with unknown clinical importance), and UMD (1 X as a causal variant). The c.8487+3A>G variant is located in the 5' splice region but does not affect the invariant +1 and +2 positions. However, positions +3 to +6 are part of the splicing consensus sequence and variants involving these positions sometimes affect splicing. In silico or computational prediction software (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predicts a greater than 10% difference in splicing in 3 of 5 different programs; however, this information is not predictive enough to assume pathogenicity. Functional analysis of the variant was performed by lymphocyte RT-PCR and hybrid minigene assays in study by Acedo (2012); the result of the c.8487+3A>G variant was found to be exon 19 skipping. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more pathogenic role for this variant. This variant is classified as predicted pathogenic. -

Hereditary breast ovarian cancer syndrome Pathogenic:1

Sep 08, 2024

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This sequence change falls in intron 19 of the BRCA2 gene. It does not directly change the encoded amino acid sequence of the BRCA2 protein. RNA analysis indicates that this variant induces altered splicing and likely results in a shortened protein product. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with Fanconi anemia and/or hereditary breast and ovarian cancer (PMID: 21548014, 23613520, 27376475). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as IVS19+3A>G. ClinVar contains an entry for this variant (Variation ID: 52603). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of exon 19, but is expected to preserve the integrity of the reading-frame (PMID: 22632462). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -

Hereditary breast ovarian cancer syndrome;C1838457:Fanconi anemia complementation group D1 Other:1

-

GenomeConnect - Invitae Patient Insights Network

Significance: not provided

Review Status: no classification provided

Collection Method: phenotyping only

Variant interpreted as Likely pathogenic and reported on 03-21-2018 by Lab Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
BayesDel_noAF	Benign	-0.30
CADD	Benign	16
DANN	Benign	0.95

Splicing

Name	Calibrated prediction	Score	Prediction
dbscSNV1_ADA	Pathogenic	0.99
dbscSNV1_RF	Pathogenic	0.84
SpliceAI score (max)		0.56		Details are displayed if max score is > 0.2
DS_DL_spliceai		0.56		Position offset: -3

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs81002806; hg19: chr13-32944697;